Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1512MR)

This product GTTS-WQ1512MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1512MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14171MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ5248MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ76MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ1716MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ8885MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ1530MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ7960MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ8158MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HL036337
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW